Alnylam Pharmaceuticals (ALNY) stock surged 6.53% in pre-market trading on Thursday following the release of its impressive second-quarter 2025 financial results. The company's performance significantly exceeded analysts' expectations, demonstrating robust growth in key areas.
The biopharmaceutical firm reported total revenues of $773.7 million for Q2 2025, marking a 17% increase compared to the same period last year. Notably, total net product revenues reached $672 million, representing a substantial 64% year-over-year growth. This surge was primarily driven by the company's TTR franchise, which generated revenues of $544 million, up 77% from the previous year.
While Alnylam's GAAP net loss per share widened to $0.51 from $0.13 in Q2 2024, its non-GAAP earnings per share of $0.34 significantly outperformed the IBES estimate of -$0.77. The company's strong performance has led it to raise its 2025 guidance, projecting total net product revenues between $2.65 billion and $2.8 billion, representing a 27% increase at the midpoint. This optimistic outlook, coupled with recent regulatory approvals and the initiation of new clinical trials, has fueled investor confidence, contributing to the stock's pre-market rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.